Get started
Author

Brandon S. Willis

Observed name: Brandon Willis
ORCID: 0009-0007-9472-4489
Observed ORCID: 0009-0007-9472-4489
OpenAlex ID: A5004904827
High Ethanol Consumption and Low Sensitivity to Ethanol-Induced Sedation in Protein Kinase A-Mutant Mice
2000 · Todd E. Thiele, Brandon Willis, et al. · Journal of Neuroscience · 176
PDF
BRD4 facilitates replication stress-induced DNA damage response
2018 · Jingwen Zhang, Austin M. Dulak, et al. · Oncogene · 101
Pyrazolopyridine Inhibitors of B-RafV600E. Part 1: The Development of Selective, Orally Bioavailable, and Efficacious Inhibitors
2011 · Steve Wenglowsky, Li Ren, et al. · ACS Medicinal Chemistry Letters · 66
Cre recombinase-dependent expression of a constitutively active mutant allele of the catalytic subunit of protein kinase A
2005 · Colleen M. Niswender, Brandon S. Willis, et al. · genesis · 43
Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
2024 · Azadeh C. Bashi, Elizabeth A. Coker, et al. · Cancer Discovery · 42
PDF
Involvement of Protein Kinase A in Patterning of the Mouse Somatosensory Cortex
2006 · Ruth F. Watson, Raja M. Abdel-Majid, et al. · Journal of Neuroscience · 40
PDF
Cell-Type Specific Expression of a Dominant Negative PKA Mutation in Mice
2011 · Brandon S. Willis, Colleen M. Niswender, et al. · PLoS ONE · 39
PDF
mTOR inhibition amplifies the anti-lymphoma effect of PI3Kβ/δ blockage in diffuse large B-cell lymphoma
2022 · Wendan Xu, Philipp Berning, et al. · Leukemia · 30
PDF
Inhibition of protein kinase A in murine enteric neurons causes lethal intestinal pseudo-obstruction
2005 · Douglas G. Howe, Christine M. Clarke, et al. · Journal of Neurobiology · 27
Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer
2024 · Cath Eberlein, Stuart C. Williamson, et al. · British Journal of Cancer · 21
PDF
Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity
2021 · Antonio Sacco, Cinzia Federico, et al. · Blood · 20
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
2023 · Lorna Hopcroft, Eleanor M. Wigmore, et al. · npj Breast Cancer · 19
PDF
Highly potent and selective 3-N-methylquinazoline-4(3H)-one based inhibitors of B-RafV600E kinase
2014 · Steve Wenglowsky, Li Ren, et al. · Bioorganic & Medicinal Chemistry Letters · 19
Potent combination benefit of the AKT inhibitor capivasertib and the BCL-2 inhibitor venetoclax in diffuse large B cell lymphoma
2024 · Brandon S. Willis, Kevin Mongeon, et al. · Leukemia · 10
PDF
The interplay between FOXO3 and FOXM1 influences sensitivity to AKT inhibition in PIK3CA and PIK3CA/PTEN altered estrogen receptor positive breast cancer
2025 · Valentina Cutano, Ming Li Chia, et al. · npj Breast Cancer · 9
PDF
A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies
2021 · Graham P. Collins, Tracy N. Clevenger, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 9
PDF
Specific Targeting of KRAS Using a Novel High-Affinity KRAS Antisense Oligonucleotide in Multiple Myeloma
2019 · Antonio Sacco, Cinzia Federico, et al. · Blood · 4
Abstract LB-263: Preclinical efficacy of the ATR inhibitor AZD6738 in combination with the BTK inhibitor acalabrutinib in ABC-DLBCL models
2018 · Lucy A. Young, Oona Delpuech, et al. · Cancer Research · 3
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
2023 · Lorna Hopcroft, Eleanor M. Wigmore, et al. · npj Breast Cancer · 2
PDF
Combination Benefit of Capivasertib and Venetoclax in Preclinical Models of Diffuse Large B-Cell Lymphoma
2021 · Brandon Willis, India Neveras, et al. · Blood · 1
Abstract 551: A potent and selective cFMS inhibitor regulates the tumor macrophage microenvironment leading to tumor growth inhibition
2011 · Albion D. Wright, Brandon S. Willis, et al. · Cancer Research · 1
Abstract 2188: Integrative transcriptomic profiling and flow cytometry analysis of AML PDX models identify purine-pyrimidine metabolic dependency shared in LSCs and blasts.
2026 · Kangsan Kim, Haiming Xu, et al. · Cancer Research
Abstract 3951: AKT inhibitor capivasertib combines with dexamethasone and venetoclax to enhance anti-tumor responses in the preclinical models of childhood acute lymphoblastic leukemia
2025 · Brandon Willis, Nadezda Bryan, et al. · Cancer Research
Abstract 3008: The interplay between FOXO3 and FOXM1 influences sensitivity to AKT inhibition in PIK3CA and PIK3CA/PTEN altered estrogen receptor positive breast cancer
2025 · Valentina Cutano, Ming Li Chia, et al. · Cancer Research
Table S9 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
2024 · Azadeh C. Bashi, Elizabeth A. Coker, et al.
Works count: 85
Citation count: 682
H-index: 13
I10-index: 14
Year
Topic
Type